Slide 1

Company Overview 2020 Wells Fargo Virtual Healthcare Conference NASDAQ: STRO Bill Newell, CEO Exhibit 99.1

Slide 2

Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our future financial performance, business plans and objectives, current and future clinical and preclinical activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, timing and success of our planned development activities, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, potential growth opportunities, financing plans, competitive position, industry environment and potential market opportunities. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors, including risks and uncertainties related to our cash forecasts, our and our collaborators’ ability to advance our product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, and the expected impact of the COVID-19 pandemic on our operations. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These factors, together with those that may be described in greater detail under the heading “Risk Factors” contained in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other reports the company files from time to time with the Securities and Exchange Commission, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we nor our management assume responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to publicly update any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Slide 3

The Sutro Vision Novel Platform Delivering on Promise to Change the Future of Oncology PLATFORM XpressCF® and XpressCF+™ Precision Protein Engineering Generates Superior Molecules Integrated Manufacturing Facility Is Strategic Asset Proven IND Engine 3 Potential Best-in-Class ADCs in Phase 1 2 more INDs projected before YE 2021 PRODUCTS PARTNERS Premier Collaborations with Robust Economics: Bristol Myers Squibb BCMA ADC in Phase 1B/2 Merck 2 Promising Cytokine derivatives EMD Serono MUC1-EGFR Bispecific ADC First in Human target 1Q21 PEOPLE Team With Track Record of Executing FINANCIAL RESOURCES Cash, cash equivalents, and marketable securities balance of $207.0M as of June 30, 2020 Does not include ~1.6M shares of Vaxcyte (Nasdaq: PCVX) valued at $49.1M as of June 30, 2020 Estimated cash runway into 2H 2022, not including new BD deals or PCVX stock sales

Slide 4

Sutro’s Approach Delivering Potentially Best-in-Class ADCs and Cytokine Conjugates Widening the Therapeutic Index is Key to Achieving Optimized Performance Rapid iterative design Selection of specific sites for conjugation for optimal performance Homogenous end-products XpressCF® – Our Truly Empirical Approach Proprietary XpressCF® rapid synthesis protein library generation, precision XpressCF+™ conjugation technology and robust medicinal chemistry enables: Optimization of known product concepts Empirical evaluation of unexplored product concepts Rapid generation of best-in-class molecules ADCs, iADCs & Targeted Therapeutics Precision delivery of active pharmacological entity with optimal attributes Cytokine Receptor Targets Rapid evolution of optimal attributes to enable systemic administration The Sutro Advantage

Slide 5

Sutro Clinical Pipeline Owned and Partnered Programs Program Discovery Preclinical Phase 1/1b Phase 2/3 Milestone Commercial Rights Ovarian and Endometrial Cancer FolRα - Targeting ADC STRO-002 CD74 - Targeting ADC STRO-001 Multiple Oncology Programs including iADCs Cytokine Derivatives Commence Dose Expansion Phase in 2H 2020 Clinical Data Presented Sep 2020 Currently in Phase 1b/2 First in Human Projected 1Q21 Lymphomas; DLBCL, Mantle Cell, Follicular Multiple Myeloma (Orphan Drug Designation) Oncology Multiple Myeloma NSCLC & sqCC (esophageal) Oncology & Autoimmune Oncology Worldwide Rights (A) (B) BCMA - Targeting ADC CC-99712 BMS automatically obtained worldwide rights to the BCMA - targeting ADC---the first collaboration product candidate to achieve IND clearance in the United States. EMD Serono, an affiliate from Merck KGaA, Darmstadt, Germany Additional Clinical Data Expected in 2H 2020 MUC1-EGFR Bispecific ADC M1231 ✅

Slide 6

Encouraging Progress Across Multiple Programs* *Based on data or events previously disclosed publicly **Based on 33 evaluable patients at ≥2.9 mg/kg STRO-002 (FolRα ADC) – OC all comers Dose escalation enrollment complete (39 patients enrolled, 34 ≥ 2.9 mg/kg & 38% remain on study) Promising Anti-Tumor Activity: 8 PRs & 13 SD ORR of 24% and DCR of 60% at ≥ 12 weeks** Durability: 44% patients on-study for ≥ 16 wks 12% patients on-study for ≥ 52 wks Encouraging CA-125 Reductions; 72% with ≥ 50% reduction in 1 or more post-baseline scans Generally well tolerated; no ocular SAEs/DLTs STRO-001 (CD74 ADC) – B Cell all comers Dose escalation on-going (33 patients dosed at less than 1.78 mg/kg) 1 CR & 1 PR out of 5 DLBCL patients; 1 SD in multiple myeloma cohort Generally well tolerated; no ocular SAEs/DLTs CC-99712 (BCMA ADC) – MM all comers Dose escalation on-going (cleared 0.5-2.0 mg/kg) N=8 as of June 2020 includes 4 patients dosed at 3.0 mg/kg with 3–6 patients projected at 4.5 mg/kg and plans for higher doses Same linker/warhead as STRO-001 (DAR = 4) M1231 (MUC1-EGFR Bispecific ADC) First in Human projected for 1Q21 – NSCLC & sqCC (esophageal) Same linker/warhead as STRO-002 (DAR = 4) 2nd of 3 major collaborations reaching IND Vaxcyte 24-Valent Pneumococcal Conjugate Vaccine IND filing projected for 2H21 Phase 1/2 in 2022

Slide 7

Delivering On Our Collaborations ~ $384 Million in Payments Received through June 30, 2020 from Collaborators Cytokine Derivatives 1st of 2 programs with lead optimization achieved in 18 months ~$101M total funding received Up to $1.6B potential future milestones for all programs Mid single digit to low teen % royalties on WW sales BCMA-targeting ADC (CC-99712): Phase 1b/2 trial for multiple myeloma (dose escalation began 2H 2019) ~$233M total funding received Up to $275M potential future milestones for CC-99712 Mid to high single digit % royalties on WW sales MUC1-EGFR Bispecific ADC (M1231): Potentially first-in-class dual antigen-targeting MUC1-EGFR Bispecific ADC ~$38M total funding received First in Human projected in 1Q2021 Up to $52.5M in potential milestones for M1231 Low to mid single digit % royalties on WW sales IND Anticipated in 2H2021: Formerly SutroVax – spinout using XpressCF+™ Potential best-in-class pneumococcal conjugate and other vaccines $288M IPO in June 2020 (NASDAQ: PCVX) Sutro owns ~$1.6M shares of common stock as of June 30, 2020 4% royalties on WW sales

Slide 8

FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002

Slide 9

STRO-002 Structure and Design Optimized molecule provides potential for best-in-class STRO 002 STRO-002 Structure of hemiasterlin linker-warhead following conjugation STRO-002 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids STRO-002 has a drug-antibody ratio of 4:1, with a proprietary cleavable hemiasterlin linker-warhead that is stable in circulation Internalization of the ADC releases hemiasterlin in the tumor cell, resulting in immunogenic cell death of cancer cells

Slide 10

Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels Data as of August 31, 2020 Characteristic Total N = 39 (%) Age, median (range), years 61 (48-79) Tumor type EOC 30 (77) Fallopian tube 7 (18) Primary peritoneal 2 (5) ECOG PS 0 23 (59) 1 16 (41) Median time from diagnosis (range) 3.9 years (0.6–17.1) Median lines of prior therapy (range) 5 (2–10) Platinum 39 (100) ≥ 3 prior platinum regimens 14 (36) Taxanes 38 (97) Bevacizumab 31 (79) PARP inhibitors 23 (59) Checkpoint inhibitors 8 (21) Experimental therapy 13 (34) Characteristic Total N = 39 (%) Dose Level of STRO-002 0.5 mg/kg, 1.0 mg/kg, 1.8 mg/kg 5 (13) 2.9 mg/kg 3 (8) 4.3 mg/kg 5 (13) 5.2 mg/kg 12 (31) 5.6 mg/kg 3 (8) 6.0 mg/kg 10 (26) 6.4 mg/kg 1 (3) STRO 002

Slide 11

STRO-002 is Generally Well Tolerated 87% of AEs were Grade 1–2 No need for prophylactic corticosteroid eyedrops Neutropenia readily reverses within 1 week, without the need for G-CSF Peripheral neuropathy/arthralgia can be managed with dose reduction/delay without evidence of compromised efficacy Safety Profile Is Encouraging

Slide 12

Best % change in sum of target lesions from baseline Evaluable patients treated at ≥ 2.9 mg/kg, N=29 4 pts off study before post baseline scan 1 pt ongoing, not yet at first post baseline scan Data as of August 31, 2020 Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients +30 +6 +19 +13 +4 +2 +1 0 -2 -3 -5 -6 -6 -11 -18 -19 -21 -22 -22 -26 -29 -32 -32 -33 -35 -44 -48 -74 -88 Patients 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 On study +6 ORR: 24% (8/33) DCR at ≥ 12 weeks: 60% (20/33) Partial response = ≥ 30% reduction

Slide 13

Partial Response with 74% Tumor Reduction Patient Continues on Treatment Confirmed PR after 4 cycles Baseline 3/16/20 06/29/20 57-year-old woman with platinum resistant ovarian cancer progressing after 4 prior regimens received STRO-002 at 5.2 mg/kg and remains on study treatment

Slide 14

Long Duration on Study and Disease Control Observed in Unenriched, Heavily Pre-Treated Ovarian Cancer Patients Duration calculated as time from first dose to last dose given (on study) or date of PD (off study). Data as of Aug 31, 2020 STRO 002 0 5 10 15 20 25 30 35 40 45 50 55 60 2.9 mg/kg 2.9 mg/kg 6.0 mg/kg 5.6 mg/kg 4.3 mg/kg 4.3 mg/kg 6.0 mg/kg 5.2 mg/kg 6.0 mg/kg 4.3 mg/kg 5.2 mg/kg 6.0 mg/kg 6.0 mg/kg 5.2 mg/kg 6.0 mg/kg 5.2 mg/kg 5.6 mg/kg 6.0 mg/kg 5.2 mg/kg 5.2 mg/kg 5.2 mg/kg 4.3 mg/kg 5.2 mg/kg 6.0 mg/kg 6.0 mg/kg 6.4 mg/kg 5.6 mg/kg 2.9 mg/kg 5.2 mg/kg 6.0 mg/kg 5.2 mg/kg 5.2 mg/kg 4.3 mg/kg 5.2 mg/kg 16 52 On study Median number of doses, all patients = 4 (range 120)   X-Axis: Weeks 44% > 16 weeks on study 12% > 52 weeks on study cPR = Confirmed partial response (PR) uPR = Unconfirmed PR cSD = Confirmed stable disease (SD) uSD = Unconfirmed SD cPR uPR uPR uPR uPR cPR uPR cSD cSD cSD cSD cSD cSD cSD uSD uSD uSD uSD uSD uSD uSD uSD uPR uSD uSD ORR: 24% (8/33) DCR at ≥ 12 weeks: 60% (20/33)

Slide 15

STRO 002 High Rates of CA-125 Responses are Associated with Anti-Tumor Activity *Gynecologic Cancer InterGroup (GCIG) criteria requires an elevated baseline CA-125 level of at least twice the upper limit of normal 10/25 (40%) have confirmed CA-125 reductions ≥ 50% that is maintained and confirmed 28 days later 9 pts not evaluable for CA-125 response per GCIG criteria* 72% (18/25) of patients with elevated CA-125 levels at baseline had ≥ 50% reduction in CA-125 in at least 1 post-treatment timepoint CA-125 decreases ≥ 50% from baseline are associated with tumor control with RECIST responses and stable disease X axis- post C1D1 assessments (weeks) Y axis- change from C1D1 CA-125 Weeks from C1D1 50% reduction Change from C1D1 100% 50% 0% -50% -100% 10 20 30 40 50

Slide 16

CA-125 Reduction in level of ≥50% 57% (12/21) 72% (18/25) STRO-002 Clinical Data Readout April 20th, 2020 Interim Analysis August 31st, 2020 Interim Analysis N ≥ 2.9 mg/kg* 25 (20 evaluable) 34 (33 evaluable) Median Age 61 (47–76) 61 (48–79) Median Prior Lines 5 (2–10) 5 (2–10) Improved Efficacy Outcomes (Increased ORR and DCR) Observed as Data Matures with Longer Follow-Up STRO 002 RECIST Responses 1 PR 8 PRs ORR 5% (1/20) of evaluable pts 24% (8/33) of evaluable pts DCR @ ≥12 Wks 40% (8/20) of evaluable pts 60% (20/33) of evaluable pts Dur. on Study Pts on Study @ 16 Wks 32% (8/25) 44% (15/34) Pts on Study @ 52 Wks n/a 12% (4/34) *38% (13/34) of patients still on study with potential to further improve efficacy outcomes

Slide 17

STRO 002 Summary and Next Steps in Clinical Development STRO-002 is clinically efficacious at multiple doses, starting at 2.9 mg/kg Dose reductions or delays were not associated with loss of anti-tumor activity Further dose optimization will be explored during dose expansion Anticipate RP2D will be in 4.3 – 5.2 mg/kg range Expansion cohort will seek to enroll less heavily pre-treated patients Monotherapy unenriched expansion cohort in ovarian cancer planned for 4Q20 Two FRα IHC assays are being compared for accuracy and consistency EOP1/2 FDA meeting planned for next year

Slide 18

CD74-Targeting ADC: Phase 1 Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001

Slide 19

STRO-001Structure and Design First-in-class Molecule with Potential for Improved Patient Outcomes STRO 001 STRO-001 STRO-001 is a novel homogeneous antibody-drug conjugate using precisely positioned non-natural amino acids STRO-001 comprises two non-cleavable maytansinoid linker-warheads (DAR=2) that are stable in circulation The active warhead derivative efficiently kills tumor cells following internalization of the ADC and was designed to minimize bystander effects Structure of maytansinoid linker-warhead following conjugation

Slide 20

Patient Demographics First 25 Patients – ASH Abstract November 2019 Characteristics Cohort A (MM) N =14 Cohort B (NHL) N=11 Total N=25 Age, median (range), years 64.5 (42–80) 64 (21–82) 64 (21–82) Median time from diagnosis in years (range) Disease Subtype, N (%) Multiple myeloma 14 (100) N/A 14 (56) Follicular lymphoma N/A 3 (27) 3 (12) Marginal zone lymphoma 1 (9) 1 (4) Mantle cell lymphoma 1 (9) 1 (4) DLBCL 4 (36) 4 (16) Burkitt’s lymphoma 1 (9) 1 (4) DLBCL/FL 1 (9) 1 (4) Median lines of prior therapy (range) Prior autologous stem cell transplant, N (%) 6 (43) 2 (18) 8 (32) Prior related donor allogeneic stem cell transplant, N (%) 1 (7) 0 1 (4) Prior unrelated donor allogeneic stem cell transplant, N(%) 0 1 (9) 1 (4) Prior CAR-T therapy, N (%) 2 (14) 1 (9) 3 (12) STRO 001 6.4 (1.3–13.6) 3.2 (1.0–29.8) 6.2 (1.0–29.8) 6.5 (3–11) 4 (2–12) 6 (2–12)

Slide 21

Generally Well Tolerated with Early Signs of Anti-Tumor Activity Presented at EHA June 2019 and Updated in ASH Abstract November 2019 STRO 001 STRO-001 was generally well tolerated, most AEs were Grade 1 & 2 No ocular toxicity signals have been observed Preliminary anti-tumor activity: DLBCL: 1CR & 1PR MM: 1 Stable disease Responses observed at doses of <1.0 mg/kg – dose escalation on-going Patients are currently screened for pre-existing thromboses and if present, the patient is administered anticoagulants before receiving initial dose Next safety & efficacy update anticipated at ASH conference in 4Q 2020

Slide 22

CC–99712 (BCMA-Targeting ADC) Phase 1B/2 Study Potential for Best-In-Class Ongoing Study of Dose Escalation (Q3W) N O OO NH OH OCH3 O N O O Cl H3CO O N O O OOOON N H O N N N Site-specific conjugation leads to Drug-antibody Ratio (DAR) = 4 CC-99712 Molecule DL3 N=1 N=1 N=4 N=3-6 0.6 mg/kg N = 2 2.0 mg/kg 1.25 mg/kg 3.0 mg/kg 4.5 mg/kg 10.0 mg/kg Dose escalation ongoing. Key data will be the therapeutic index vs competitor. Control of DAR could be advantageous in terms of patient safety and efficacy. CC-99712 (Payload: non- cleavable Maytansinoid Source: BMS Investor Series Day 1, Slide 33 – Early Pipeline and Immuno-Oncology, Presentation June 22, 2020 DL1 DL2 DL4 DL7 DL5 DL6 6.7 mg/kg

Slide 23

M1231 (MUC1-EGFR Bispecific ADC) Potential for First-In-Class – 1Q21 First In Human Planned First bispecific ADC to go to clinic; M1231 targets MUC1 & EGFR Combines next generation technologies; stable site-specific XpressCF+™ conjugation, optimized positioning of a proprietary hemiasterlin payload and SEED antibody structure Efficient uptake into tumor cells, leading to improved preclinical efficacy compared to monospecific variants Potentially reduced risk for on-target toxicities based on limited target co-expression in normal tissues First in human study planned for 1Q2021 with focus on NSCLC & esophageal squamous cell carcinoma MUC1 EGFR scFV Fab Source: Anderl, J. M1231: A first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1. In: AACR Virtual Meeting II; 2020 June 22-24. Minisymposium MS.ET03.01

Slide 24

A single M1231 application was associated with complete remission in a subset of preclinical NSCLS and sqCC esophageal PDX models Tumor response seems to be associated with target expression M1231 (MUC1-EGFR Bispecific ADC) Strong efficacy in preclinical NSCLC & esophageal cancer PDX models Source: Anderl, J. M1231: A first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1. In: AACR Virtual Meeting II; 2020 June 22-24. Minisymposium MS.ET03.01

Slide 25

Sutro’s Next Generation Tumor Targeting Immunostimulatory ADC Off the shelf, systemically administered in situ immunization Breakthrough technology for dual conjugated immunostimulatory antibody drug conjugate Designed and enabled using Sutro’s XpressCF+TM platform Enables simultaneous and precise tumor targeting of a cytotoxin and a novel toll-like receptor (TLR) agonist with systemic delivery Novel design intended to prime an adaptive anti-tumor response in a monotherapy Potential to reprogram the patient’s tumor microenvironment and generate protective anti-tumor immunity Data Presented at the World ADC Meeting in London, 3/2020 iADC

Slide 26

Immunostimulatory ADC Provides Enhanced Immune Cell Activation and Anti-Tumor Immunity Early activation of Dendritic Cells Spleen of treated mice Control iADC (Cytotoxin + TLR agonist) ADC (Cytotoxin alone) ISAC (TLR agonist alone) iADC single dose causes some complete responses MC38-hFolR mouse model iADC treated mice resistant to future re-challenge Simultaneous delivery of cytotoxic payload and TLR agonist drives complete responses iADC induces the release of tumor antigens and antigen-presenting cell function to prime anti-tumor memory responses Systemically delivered monotherapy with potential to induce in situ immunization iADC (iADC)

Slide 27

Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD Chief Scientific Officer Arturo Molina, MD, MS, FACP Chief Medical Officer Ed Albini Chief Financial Officer Shabbir Anik, PhD Chief Technical Operations Officer Linda Fitzpatrick Chief People and Communications Officer Nicki Vasquez, PhD Sr. VP Alliance Management / Portfolio Strategy & Operations Lynx Neurex

Slide 28

Company Overview 2020 Wells Fargo Virtual Healthcare Conference NASDAQ: STRO Bill Newell, CEO